The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Blujepa sets itself apart from nitrofurantoin as ... To put it simply, the drug is designed to specifically inhibit bacterial DNA in the E. coli class, which causes the majority of UTI infections ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years ... In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs.

Results of two phase III trials -- EAGLE-2 and EAGLE-3-- supported approval, demonstrating that the first-in-class antibiotic was noninferior to nitrofurantoin, a standard option for uncomplicated ...

In the EAGLE-3 experiment, gepotidacin was statistically superior to nitrofurantoin. “As a first-in-class investigational oral antibiotic with activity against common uropathogens, including ...

47% in patients treated with nitrofurantoin ... the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.